GlassScriptPhysician profile
George A Sprecace
NPI 1891792529
$1,423.69
in general payments reported to CMS, 2019-2025
8 companies · $17.24 in 2025
The $17.24 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $82.25 · 2021: $250 · 2022: $270 · 2023: $386 · 2024: $144 · 2025: $17.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546 · Education: $1.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.52 |
| Education | $1.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $376.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $278.93 | 2019-2024 | Tezspire |
| Glaxosmithkline, LLC. | $215.31 | 2019-2024 | Nucala, Arexvy |
| Abbvie INC. | $171.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $161.16 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $107.04 | 2019-2022 | |
| Genentech USA, INC. | $102.51 | 2019-2024 | Xolair |
| Mylan Specialty L.P. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Sprecace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.